Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.55
MNKD's Cash to Debt is ranked higher than
55% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. MNKD: 0.55 )
MNKD' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.55

F-Score: 3
Z-Score: -7.54
M-Score: -5.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROA (%) -66.09
MNKD's ROA (%) is ranked higher than
61% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. MNKD: -66.09 )
MNKD' s 10-Year ROA (%) Range
Min: -393.74   Max: -52.52
Current: -66.09

-393.74
-52.52
ROC (Joel Greenblatt) (%) -97.68
MNKD's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. MNKD: -97.68 )
MNKD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -570.67   Max: -71.09
Current: -97.68

-570.67
-71.09
EBITDA Growth (3Y)(%) -28.90
MNKD's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. MNKD: -28.90 )
MNKD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -43   Max: 10.9
Current: -28.9

-43
10.9
EPS Growth (3Y)(%) -27.20
MNKD's EPS Growth (3Y)(%) is ranked higher than
66% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. MNKD: -27.20 )
MNKD' s 10-Year EPS Growth (3Y)(%) Range
Min: -42.9   Max: 7.6
Current: -27.2

-42.9
7.6
» MNKD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MNKD Guru Trades in Q1 2014

Murray Stahl 134,495 sh (+26.63%)
Steven Cohen 103,800 sh (-27.47%)
» More
Q2 2014

MNKD Guru Trades in Q2 2014

Jim Simons 1,769,800 sh (New)
Paul Tudor Jones 29,250 sh (New)
Murray Stahl 73,850 sh (-45.09%)
» More
Q3 2014

MNKD Guru Trades in Q3 2014

Murray Stahl 137,271 sh (+85.88%)
Jim Simons Sold Out
Paul Tudor Jones 11,246 sh (-61.55%)
» More
Q4 2014

MNKD Guru Trades in Q4 2014

Jim Simons 893,852 sh (New)
Murray Stahl 158,109 sh (+15.18%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 Sold Out 0.01%$2.31 - $3.56 $ 5.73108%0
Jean-Marie Eveillard 2012-12-31 New Buy0.01%$1.85 - $2.83 $ 5.73165%800000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -14.92
MNKD's EV-to-EBIT is ranked higher than
64% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MNKD: -14.92 )
MNKD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -14.92

Current Ratio 0.50
MNKD's Current Ratio is ranked higher than
50% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. MNKD: 0.50 )
MNKD' s 10-Year Current Ratio Range
Min: 0.23   Max: 10
Current: 0.5

0.23
10
Quick Ratio 0.47
MNKD's Quick Ratio is ranked higher than
51% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. MNKD: 0.47 )
MNKD' s 10-Year Quick Ratio Range
Min: 0.23   Max: 10
Current: 0.47

0.23
10

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -6.70
MNKD's Earnings Yield (Greenblatt) is ranked higher than
71% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. MNKD: -6.70 )
MNKD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.5   Max: 0
Current: -6.7

-9.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NNF1.Germany,
MannKind Corp a development stage biopharmaceutical company, was incorporated in the state of Delaware on February 14, 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other product MKC253, MKC253 is a Technosphere formulation of GLP-1. Results from a phase 1 trial supported the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with type 2 diabetes. Products manufactured in the United States and marketed outside the United States are subject to certain FDA regulations, as well as regulation by the country in which the products are to be sold.
» More Articles for MNKD

Headlines

Articles On GuruFocus.com
own Mar 02 2015 
investment Feb 28 2015 
Analysts Weigh in on MannKind Following Q4 Results Feb 27 2015 
Portfolio 1 Jan 03 2015 
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 

More From Other Websites
US STOCKS-Wall St falls from records, led by technology stocks Mar 03 2015
US STOCKS-Wall St falls from records, led by technology stocks Mar 03 2015
MannKind's Charts Suggest Waiting on the Stock After Goldman's Downgrade Mar 03 2015
Goldman Downgrades MannKind To Sell, Should You Follow Their Lead? Mar 03 2015
Goldman Sachs Slams MannKind, Shares Down 9% Mar 03 2015
Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation' Mar 03 2015
MannKind's Short Interest Has 'Grown High,' Analyst Says Mar 03 2015
Why MannKind Could Lose Half Its Value Mar 03 2015
Goldman Sachs Says MannKind Has 55% Downside Mar 03 2015
Cramer's Stop Trading: Goldman unkind to Mankind Mar 03 2015
4 Biotechs Expected to See Huge Buying on PowerShares Rebalance Mar 03 2015
If You 'Want To Make A Good Drug Great' Cost Must Be Factored In Mar 03 2015
MannKind Rating, Price Target Are Cut by Goldman on Slow Afrezza Launch Mar 03 2015
Will MannKind Finally Reach A Solid Ground? Mar 02 2015
MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter Mar 02 2015
Afrezza's Initial Sales Create Buying Opportunity Feb 27 2015
Jefferies Expects Exciting 2015 For MannKind Feb 26 2015
MannKind: 'Encouraged By Early Feedback' on Afrezza Launch Feb 26 2015
Short Sellers Increase Bets Against Biotech as Shares Continue to Rise Feb 26 2015
JPM Securities Picks Through Biotech News For Winners Feb 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK